vs
Cardio Diagnostics Holdings, Inc.（CDIO）与SPRUCE BIOSCIENCES, INC.（SPRB）财务数据对比。点击上方公司名可切换其他公司
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
Spruce Biosciences是一家后期生物制药企业，专注于开发存在高度未满足医疗需求的罕见内分泌及代谢疾病的靶向疗法，核心管线涵盖先天性肾上腺增生、库欣综合征等适应症，主要服务北美、欧洲等发达市场患者。
CDIO vs SPRB — 直观对比
营收规模更大
CDIO
是对方的Infinity倍
$0
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $0 |
| 净利润 | — | $-14.6M |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | -21.2% | — |
| 净利润同比 | 3.6% | 37.8% |
| 每股收益（稀释后） | — | $-32.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIOSPRB
| Q4 25 | $3.6K | $0 | ||
| Q3 25 | $2.9K | $0 | ||
| Q2 25 | $7.5K | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | $4.5K | $697.0K | ||
| Q3 24 | $6.6K | $602.0K | ||
| Q2 24 | $7.9K | $1.6M | ||
| Q1 24 | $15.9K | $2.0M |
净利润CDIOSPRB
| Q4 25 | — | $-14.6M | ||
| Q3 25 | $-1.7M | $-8.2M | ||
| Q2 25 | $-1.7M | $-2.1M | ||
| Q1 25 | — | $-14.0M | ||
| Q4 24 | — | $-23.6M | ||
| Q3 24 | $-1.4M | $-8.7M | ||
| Q2 24 | $-1.3M | $-9.2M | ||
| Q1 24 | $-4.2M | $-11.6M |
营业利润率CDIOSPRB
| Q4 25 | — | — | ||
| Q3 25 | -59950.9% | — | ||
| Q2 25 | -22457.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3453.9% | ||
| Q3 24 | -21412.9% | -1562.8% | ||
| Q2 24 | -16295.6% | -623.4% | ||
| Q1 24 | -26105.3% | -631.0% |
净利率CDIOSPRB
| Q4 25 | — | — | ||
| Q3 25 | -60053.8% | — | ||
| Q2 25 | -22517.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3380.1% | ||
| Q3 24 | -21467.6% | -1440.4% | ||
| Q2 24 | -16365.9% | -570.2% | ||
| Q1 24 | -26140.0% | -580.7% |
每股收益（稀释后）CDIOSPRB
| Q4 25 | — | $-32.43 | ||
| Q3 25 | $-0.98 | $-14.58 | ||
| Q2 25 | $-0.97 | $-3.50 | ||
| Q1 25 | — | $-0.32 | ||
| Q4 24 | — | $-63.64 | ||
| Q3 24 | $-1.73 | $-15.75 | ||
| Q2 24 | $-1.71 | $-16.73 | ||
| Q1 24 | $-5.93 | $-0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $48.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.0M | $42.5M |
| 总资产 | $7.8M | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDIOSPRB
| Q4 25 | — | $48.9M | ||
| Q3 25 | — | $10.7M | ||
| Q2 25 | — | $16.4M | ||
| Q1 25 | — | $25.6M | ||
| Q4 24 | — | $38.8M | ||
| Q3 24 | — | $60.1M | ||
| Q2 24 | — | $69.7M | ||
| Q1 24 | — | $81.2M |
总债务CDIOSPRB
| Q4 25 | — | — | ||
| Q3 25 | — | $549.0K | ||
| Q2 25 | — | $972.0K | ||
| Q1 25 | — | $1.4M | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $2.8M | ||
| Q1 24 | — | $3.2M |
股东权益CDIOSPRB
| Q4 25 | $7.0M | $42.5M | ||
| Q3 25 | $8.2M | $5.4M | ||
| Q2 25 | $9.7M | $13.2M | ||
| Q1 25 | — | $15.3M | ||
| Q4 24 | $9.6M | $28.8M | ||
| Q3 24 | $3.7M | $51.6M | ||
| Q2 24 | $3.1M | $59.2M | ||
| Q1 24 | $3.0M | $66.6M |
总资产CDIOSPRB
| Q4 25 | $7.8M | $53.0M | ||
| Q3 25 | $8.8M | $15.3M | ||
| Q2 25 | $10.4M | $21.8M | ||
| Q1 25 | — | $31.6M | ||
| Q4 24 | $10.6M | $45.2M | ||
| Q3 24 | $4.5M | $65.1M | ||
| Q2 24 | $4.0M | $75.5M | ||
| Q1 24 | $4.3M | $87.5M |
负债/权益比CDIOSPRB
| Q4 25 | — | — | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 0.06× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.05× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $-6.5M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | — |
| 自由现金流率自由现金流/营收 | -166361.5% | — |
| 资本支出强度资本支出/营收 | 5269.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.3M | — |
8季度趋势，按日历期对齐
经营现金流CDIOSPRB
| Q4 25 | $-5.7M | $-6.5M | ||
| Q3 25 | $-1.4M | $-5.3M | ||
| Q2 25 | $-1.6M | $-8.8M | ||
| Q1 25 | — | $-12.7M | ||
| Q4 24 | $-5.0M | $-20.7M | ||
| Q3 24 | $-1.2M | $-9.2M | ||
| Q2 24 | $-1.2M | $-11.1M | ||
| Q1 24 | $-1.2M | $-15.0M |
自由现金流CDIOSPRB
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-1.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-5.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-1.3M | — |
自由现金流率CDIOSPRB
| Q4 25 | -166361.5% | — | ||
| Q3 25 | -54509.7% | — | ||
| Q2 25 | -21273.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -115422.6% | — | ||
| Q3 24 | -17942.3% | — | ||
| Q2 24 | -17513.3% | — | ||
| Q1 24 | -7866.9% | — |
资本支出强度CDIOSPRB
| Q4 25 | 5269.1% | — | ||
| Q3 25 | 5703.5% | — | ||
| Q2 25 | 250.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4759.9% | — | ||
| Q3 24 | 353.3% | — | ||
| Q2 24 | 2133.4% | — | ||
| Q1 24 | 125.5% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
